Chronic glomerulonephritis (CGN) is a heterogeneous, immune-mediated inflammatory syndrome that inexorably progresses toward end-stage kidney disease. It follows a progressively deteriorating course and may ultimately progress to end-stage renal disease. Western medicine treatment of this disease is mainly to control hypertension, reduce urinary protein, improve renal microcirculation and other symptoms. Although the symptoms can be controlled, there are many side effects and limited efficacy, which is difficult to fully meet the clinical needs. Concomitant Chinese medicine mitigates adverse spectra while amplifying therapeutic yield. Studies have found that p38 mitogen-activated protein kinase, transforming growth factor-β1/Smad, Toll-like receptor 4/myeloid differentiation primary response protein 88/nuclear factor-κB, lipopolysaccharide binding protein/differentiation cluster 14/FBJ murine osteosarcoma virus oncogene homolog monocyte chemoattractant protein-1/CC chemokine receptor 2 and other key signaling pathways play a key role in the pathogenesis of CGN, and traditional Chinese medicine can play an anti-inflammatory, anti-oxidation, anti-fibrosis and promotion of local microcirculation. Due to its diverse mechanisms of action and multi-target actions, integrated traditional Chinese and Western medicine has shown high safety and good tolerance in clinical applications, and has gradually become an important part of the modern treatment system.